---
document_datetime: 2025-11-23 07:32:04
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/cyltezo.html
document_name: cyltezo.html
version: success
processing_time: 0.0970537
conversion_datetime: 2025-12-24 02:28:09.195007
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Cyltezo

[RSS](/en/individual-human-medicine.xml/65462)

##### Withdrawn

This medicine's authorisation has been withdrawn

adalimumab

Medicine

Human

Withdrawn

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Cyltezo](#news-on)
- [Related content](#related-content-445)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

On 15 January 2019, the European Commission withdrew the marketing authorisation for Cyltezo (adalimumab) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, Boehringer Ingelheim International GmbH, which notified the European Commission of its decision not to market the product in the EU for commercial reasons.

Cyltezo was granted marketing authorisation in the EU on 10 November 2017 for treatment of Rheumatoid arthritis, Juvenile idiopathic arthritis, Axial spondyloarthritis, Psoriatic arthritis, Psoriasis, Paediatric plaque psoriasis, Hidradenitis suppurativa (HS), Crohn's disease, Paediatric Crohn's disease, Ulcerative colitis, Uveitis, Paediatric Uveitis. The marketing authorisation was initially valid for a 5-year period. The product had never been marketed in the EU.

Cyltezo is a biosimilar medicine of Humira. There are other biosimilar medicinal products of Humira authorised and marketed in the EU.

The European Public Assessment Report (EPAR) for Cyltezo is updated accordingly to reflect the fact that the marketing authorisation is no longer valid.

Cyltezo : EPAR - Summary for the public

English (EN) (228.67 KB - PDF)

**First published:** 17/11/2017

**Last updated:** 17/11/2017

[View](/en/documents/overview/cyltezo-epar-summary-public_en.pdf)

[Other languages (22)](#file-language-dropdown-63)

български (BG) (303.47 KB - PDF)

**First published:**

17/11/2017

**Last updated:**

17/11/2017

[View](/bg/documents/overview/cyltezo-epar-summary-public_bg.pdf)

español (ES) (229.91 KB - PDF)

**First published:**

17/11/2017

**Last updated:**

17/11/2017

[View](/es/documents/overview/cyltezo-epar-summary-public_es.pdf)

čeština (CS) (278.66 KB - PDF)

**First published:**

17/11/2017

**Last updated:**

17/11/2017

[View](/cs/documents/overview/cyltezo-epar-summary-public_cs.pdf)

dansk (DA) (227.93 KB - PDF)

**First published:**

17/11/2017

**Last updated:**

17/11/2017

[View](/da/documents/overview/cyltezo-epar-summary-public_da.pdf)

Deutsch (DE) (236.32 KB - PDF)

**First published:**

17/11/2017

**Last updated:**

17/11/2017

[View](/de/documents/overview/cyltezo-epar-summary-public_de.pdf)

eesti keel (ET) (225.43 KB - PDF)

**First published:**

17/11/2017

**Last updated:**

17/11/2017

[View](/et/documents/overview/cyltezo-epar-summary-public_et.pdf)

ελληνικά (EL) (311.51 KB - PDF)

**First published:**

17/11/2017

**Last updated:**

17/11/2017

[View](/el/documents/overview/cyltezo-epar-summary-public_el.pdf)

français (FR) (234.64 KB - PDF)

**First published:**

17/11/2017

**Last updated:**

17/11/2017

[View](/fr/documents/overview/cyltezo-epar-summary-public_fr.pdf)

hrvatski (HR) (253.28 KB - PDF)

**First published:**

17/11/2017

**Last updated:**

17/11/2017

[View](/hr/documents/overview/cyltezo-epar-summary-public_hr.pdf)

italiano (IT) (227.01 KB - PDF)

**First published:**

17/11/2017

**Last updated:**

17/11/2017

[View](/it/documents/overview/cyltezo-epar-summary-public_it.pdf)

latviešu valoda (LV) (274.15 KB - PDF)

**First published:**

17/11/2017

**Last updated:**

17/11/2017

[View](/lv/documents/overview/cyltezo-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (258.6 KB - PDF)

**First published:**

17/11/2017

**Last updated:**

17/11/2017

[View](/lt/documents/overview/cyltezo-epar-summary-public_lt.pdf)

magyar (HU) (268.14 KB - PDF)

**First published:**

17/11/2017

**Last updated:**

17/11/2017

[View](/hu/documents/overview/cyltezo-epar-summary-public_hu.pdf)

Malti (MT) (278.86 KB - PDF)

**First published:**

17/11/2017

**Last updated:**

17/11/2017

[View](/mt/documents/overview/cyltezo-epar-summary-public_mt.pdf)

Nederlands (NL) (229.07 KB - PDF)

**First published:**

17/11/2017

**Last updated:**

17/11/2017

[View](/nl/documents/overview/cyltezo-epar-summary-public_nl.pdf)

polski (PL) (284.74 KB - PDF)

**First published:**

17/11/2017

**Last updated:**

17/11/2017

[View](/pl/documents/overview/cyltezo-epar-summary-public_pl.pdf)

português (PT) (233.12 KB - PDF)

**First published:**

17/11/2017

**Last updated:**

17/11/2017

[View](/pt/documents/overview/cyltezo-epar-summary-public_pt.pdf)

română (RO) (257.84 KB - PDF)

**First published:**

17/11/2017

**Last updated:**

17/11/2017

[View](/ro/documents/overview/cyltezo-epar-summary-public_ro.pdf)

slovenčina (SK) (277.14 KB - PDF)

**First published:**

17/11/2017

**Last updated:**

17/11/2017

[View](/sk/documents/overview/cyltezo-epar-summary-public_sk.pdf)

slovenščina (SL) (269.98 KB - PDF)

**First published:**

17/11/2017

**Last updated:**

17/11/2017

[View](/sl/documents/overview/cyltezo-epar-summary-public_sl.pdf)

Suomi (FI) (226.93 KB - PDF)

**First published:**

17/11/2017

**Last updated:**

17/11/2017

[View](/fi/documents/overview/cyltezo-epar-summary-public_fi.pdf)

svenska (SV) (227.74 KB - PDF)

**First published:**

17/11/2017

**Last updated:**

17/11/2017

[View](/sv/documents/overview/cyltezo-epar-summary-public_sv.pdf)

## Product information

Cyltezo : EPAR - Product Information

English (EN) (1.64 MB - PDF)

**First published:** 17/11/2017

**Last updated:** 12/11/2018

[View](/en/documents/product-information/cyltezo-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-175)

български (BG) (2.79 MB - PDF)

**First published:**

17/11/2017

**Last updated:**

12/11/2018

[View](/bg/documents/product-information/cyltezo-epar-product-information_bg.pdf)

español (ES) (1.43 MB - PDF)

**First published:**

17/11/2017

**Last updated:**

12/11/2018

[View](/es/documents/product-information/cyltezo-epar-product-information_es.pdf)

čeština (CS) (2.22 MB - PDF)

**First published:**

17/11/2017

**Last updated:**

12/11/2018

[View](/cs/documents/product-information/cyltezo-epar-product-information_cs.pdf)

dansk (DA) (1.45 MB - PDF)

**First published:**

17/11/2017

**Last updated:**

12/11/2018

[View](/da/documents/product-information/cyltezo-epar-product-information_da.pdf)

Deutsch (DE) (1.66 MB - PDF)

**First published:**

17/11/2017

**Last updated:**

12/11/2018

[View](/de/documents/product-information/cyltezo-epar-product-information_de.pdf)

eesti keel (ET) (1.58 MB - PDF)

**First published:**

17/11/2017

**Last updated:**

12/11/2018

[View](/et/documents/product-information/cyltezo-epar-product-information_et.pdf)

ελληνικά (EL) (2.83 MB - PDF)

**First published:**

17/11/2017

**Last updated:**

12/11/2018

[View](/el/documents/product-information/cyltezo-epar-product-information_el.pdf)

français (FR) (1.75 MB - PDF)

**First published:**

17/11/2017

**Last updated:**

12/11/2018

[View](/fr/documents/product-information/cyltezo-epar-product-information_fr.pdf)

hrvatski (HR) (1.59 MB - PDF)

**First published:**

17/11/2017

**Last updated:**

12/11/2018

[View](/hr/documents/product-information/cyltezo-epar-product-information_hr.pdf)

íslenska (IS) (1.65 MB - PDF)

**First published:**

17/11/2017

**Last updated:**

12/11/2018

[View](/is/documents/product-information/cyltezo-epar-product-information_is.pdf)

italiano (IT) (1.55 MB - PDF)

**First published:**

17/11/2017

**Last updated:**

12/11/2018

[View](/it/documents/product-information/cyltezo-epar-product-information_it.pdf)

latviešu valoda (LV) (2.14 MB - PDF)

**First published:**

17/11/2017

**Last updated:**

12/11/2018

[View](/lv/documents/product-information/cyltezo-epar-product-information_lv.pdf)

lietuvių kalba (LT) (1.5 MB - PDF)

**First published:**

17/11/2017

**Last updated:**

12/11/2018

[View](/lt/documents/product-information/cyltezo-epar-product-information_lt.pdf)

magyar (HU) (2.28 MB - PDF)

**First published:**

17/11/2017

**Last updated:**

12/11/2018

[View](/hu/documents/product-information/cyltezo-epar-product-information_hu.pdf)

Malti (MT) (2.34 MB - PDF)

**First published:**

17/11/2017

**Last updated:**

12/11/2018

[View](/mt/documents/product-information/cyltezo-epar-product-information_mt.pdf)

Nederlands (NL) (1.56 MB - PDF)

**First published:**

17/11/2017

**Last updated:**

12/11/2018

[View](/nl/documents/product-information/cyltezo-epar-product-information_nl.pdf)

norsk (NO) (1.5 MB - PDF)

**First published:**

17/11/2017

**Last updated:**

12/11/2018

[View](/no/documents/product-information/cyltezo-epar-product-information_no.pdf)

polski (PL) (2.23 MB - PDF)

**First published:**

17/11/2017

**Last updated:**

12/11/2018

[View](/pl/documents/product-information/cyltezo-epar-product-information_pl.pdf)

português (PT) (1.56 MB - PDF)

**First published:**

17/11/2017

**Last updated:**

12/11/2018

[View](/pt/documents/product-information/cyltezo-epar-product-information_pt.pdf)

română (RO) (1.73 MB - PDF)

**First published:**

17/11/2017

**Last updated:**

12/11/2018

[View](/ro/documents/product-information/cyltezo-epar-product-information_ro.pdf)

slovenčina (SK) (2.31 MB - PDF)

**First published:**

17/11/2017

**Last updated:**

12/11/2018

[View](/sk/documents/product-information/cyltezo-epar-product-information_sk.pdf)

slovenščina (SL) (2.09 MB - PDF)

**First published:**

17/11/2017

**Last updated:**

12/11/2018

[View](/sl/documents/product-information/cyltezo-epar-product-information_sl.pdf)

Suomi (FI) (1.42 MB - PDF)

**First published:**

17/11/2017

**Last updated:**

12/11/2018

[View](/fi/documents/product-information/cyltezo-epar-product-information_fi.pdf)

svenska (SV) (1.44 MB - PDF)

**First published:**

17/11/2017

**Last updated:**

12/11/2018

[View](/sv/documents/product-information/cyltezo-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** IB/0005/G 15/01/2019

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Cyltezo : EPAR - All Authorised presentations

English (EN) (150.29 KB - PDF)

**First published:** 17/11/2017

**Last updated:** 17/11/2017

[View](/en/documents/all-authorised-presentations/cyltezo-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-810)

български (BG) (162.5 KB - PDF)

**First published:**

17/11/2017

**Last updated:**

17/11/2017

[View](/bg/documents/all-authorised-presentations/cyltezo-epar-all-authorised-presentations_bg.pdf)

español (ES) (149.83 KB - PDF)

**First published:**

17/11/2017

**Last updated:**

17/11/2017

[View](/es/documents/all-authorised-presentations/cyltezo-epar-all-authorised-presentations_es.pdf)

čeština (CS) (156.55 KB - PDF)

**First published:**

17/11/2017

**Last updated:**

17/11/2017

[View](/cs/documents/all-authorised-presentations/cyltezo-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (151.26 KB - PDF)

**First published:**

17/11/2017

**Last updated:**

17/11/2017

[View](/da/documents/all-authorised-presentations/cyltezo-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (151.41 KB - PDF)

**First published:**

17/11/2017

**Last updated:**

17/11/2017

[View](/de/documents/all-authorised-presentations/cyltezo-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (148.47 KB - PDF)

**First published:**

17/11/2017

**Last updated:**

17/11/2017

[View](/et/documents/all-authorised-presentations/cyltezo-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (175.9 KB - PDF)

**First published:**

17/11/2017

**Last updated:**

17/11/2017

[View](/el/documents/all-authorised-presentations/cyltezo-epar-all-authorised-presentations_el.pdf)

français (FR) (150.33 KB - PDF)

**First published:**

17/11/2017

**Last updated:**

17/11/2017

[View](/fr/documents/all-authorised-presentations/cyltezo-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (149.77 KB - PDF)

**First published:**

17/11/2017

**Last updated:**

17/11/2017

[View](/hr/documents/all-authorised-presentations/cyltezo-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (150.77 KB - PDF)

**First published:**

17/11/2017

**Last updated:**

17/11/2017

[View](/is/documents/all-authorised-presentations/cyltezo-epar-all-authorised-presentations_is.pdf)

italiano (IT) (149.21 KB - PDF)

**First published:**

17/11/2017

**Last updated:**

17/11/2017

[View](/it/documents/all-authorised-presentations/cyltezo-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (156.32 KB - PDF)

**First published:**

17/11/2017

**Last updated:**

17/11/2017

[View](/lv/documents/all-authorised-presentations/cyltezo-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (149.86 KB - PDF)

**First published:**

17/11/2017

**Last updated:**

17/11/2017

[View](/lt/documents/all-authorised-presentations/cyltezo-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (156.29 KB - PDF)

**First published:**

17/11/2017

**Last updated:**

17/11/2017

[View](/hu/documents/all-authorised-presentations/cyltezo-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (158.14 KB - PDF)

**First published:**

17/11/2017

**Last updated:**

17/11/2017

[View](/mt/documents/all-authorised-presentations/cyltezo-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (157.32 KB - PDF)

**First published:**

17/11/2017

**Last updated:**

17/11/2017

[View](/nl/documents/all-authorised-presentations/cyltezo-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (151 KB - PDF)

**First published:**

17/11/2017

**Last updated:**

17/11/2017

[View](/no/documents/all-authorised-presentations/cyltezo-epar-all-authorised-presentations_no.pdf)

polski (PL) (156.73 KB - PDF)

**First published:**

17/11/2017

**Last updated:**

17/11/2017

[View](/pl/documents/all-authorised-presentations/cyltezo-epar-all-authorised-presentations_pl.pdf)

português (PT) (150.48 KB - PDF)

**First published:**

17/11/2017

**Last updated:**

17/11/2017

[View](/pt/documents/all-authorised-presentations/cyltezo-epar-all-authorised-presentations_pt.pdf)

română (RO) (150.15 KB - PDF)

**First published:**

17/11/2017

**Last updated:**

17/11/2017

[View](/ro/documents/all-authorised-presentations/cyltezo-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (156.49 KB - PDF)

**First published:**

17/11/2017

**Last updated:**

17/11/2017

[View](/sk/documents/all-authorised-presentations/cyltezo-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (162.99 KB - PDF)

**First published:**

17/11/2017

**Last updated:**

17/11/2017

[View](/sl/documents/all-authorised-presentations/cyltezo-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (148.33 KB - PDF)

**First published:**

17/11/2017

**Last updated:**

17/11/2017

[View](/fi/documents/all-authorised-presentations/cyltezo-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (149.67 KB - PDF)

**First published:**

17/11/2017

**Last updated:**

17/11/2017

[View](/sv/documents/all-authorised-presentations/cyltezo-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Cyltezo Active substance adalimumab International non-proprietary name (INN) or common name adalimumab Therapeutic area (MeSH)

- Hidradenitis Suppurativa
- Arthritis, Psoriatic
- Psoriasis
- Crohn Disease
- Arthritis, Juvenile Rheumatoid
- Uveitis
- Arthritis, Rheumatoid
- Colitis, Ulcerative
- Spondylitis, Ankylosing

Anatomical therapeutic chemical (ATC) code L04AB04

### Pharmacotherapeutic group

Immunosuppressants

### Therapeutic indication

Please refer to section 4.1 of the Summary of product characteristics in the product information document.

## Authorisation details

EMA product number EMEA/H/C/004319

Biosimilar

This is a biosimilar medicine, which is a biological medicine highly similar to another already approved biological medicine called the 'reference medicine'. For more information, see [Biosimilar medicines](/node/68323) .

Marketing authorisation holder

Boehringer Ingelheim International GmbH

Binger Strasse 173 55216

Marketing authorisation issued 10/11/2017 Withdrawal of marketing authorisation 15/01/2019 Revision 2

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Cyltezo : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (212.2 KB - PDF)

**First published:** 21/03/2018

**Last updated:** 12/11/2018

[View](/en/documents/procedural-steps-after/cyltezo-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf)

## Initial marketing authorisation documents

Cyltezo : EPAR - Public assessment report

Reference Number: EMA/CHMP/750187/2017

English (EN) (4.54 MB - PDF)

**First published:** 17/11/2017

**Last updated:** 17/11/2017

[View](/en/documents/assessment-report/cyltezo-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Cyltezo

Reference Number: EMA/CHMP/532447/2017

English (EN) (230.82 KB - PDF)

**First published:** 15/09/2017

**Last updated:** 15/09/2017

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-cyltezo_en.pdf)

#### News on Cyltezo

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 11 to 14 September 2017](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-11-14-september-2017) 15/09/2017

#### Related content

- [Biosimilar medicines](/en/human-regulatory/overview/biosimilar-medicines)

**This page was last updated on** 06/03/2019

## Share this page

[Back to top](#main-content)